Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Breast Cancer
Interventions: RealRisks; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 35 Years to 74 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: semaglutide, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 957 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Anaheim, California • San Diego, California • Golden, Colorado + 18 more

Conditions: Healthy
Interventions: Lu AG06474, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cancer, Ovarian, Chemotherapy Effect, Calorie Deficiency, Fasting, Intermittent
Interventions: Fasting Mimicking Diet, Chemotherapy; Other · Drug
Lead sponsor: L-Nutra Inc; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Mitochondrial Myopathy
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement · Drug
Lead sponsor: Ralitza Gavrilova; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity, Overweight, Weight Loss
Interventions: Physician Counseling, Health Educator, Phone Counseling, Health promotion materials on physical activity and nutrition; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 11 Years to 13 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Stroke
Interventions: Virtual-reality based dance training; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Menorrhagia
Interventions: tranexamic acid; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 12 Years to 16 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cypress, California

Conditions: Type2 Diabetes
Interventions: No exercise, Morning exercise, Evening exercise; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 25 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Hot Flashes
Interventions: Paced respiration, Sham comparator: fast shallow breathing; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pharmacokinetics
Interventions: PrimeC-ER 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg; Drug
Lead sponsor: NeuroSense Therapeutics Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Renal Insufficiency
Interventions: Abiraterone acetate: participants with end-stage renal disease, Abiraterone acetate: matched control participants with normal renal function; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Hiv, Diabetes Mellitus, Type 2
Interventions: Subcutaneous adipose tissue biopsy, CT scan, Oral glucose tolerance test, Blood collection; Procedure · Radiation · Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lactose Intolerance
Interventions: RP-G28; Drug
Lead sponsor: Ritter Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 1 Diabetes
Interventions: LY900014, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia • West Des Moines, Iowa • Minneapolis, Minnesota

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more

Conditions: Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma
Interventions: TMZ, E7016; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pharmacokinetics, Drug Interactions
Interventions: Dasatinib ASD, Omeprazole 40 MG; Drug
Lead sponsor: Xspray Pharma AB; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Microbiome Analysis, Metabolomics
Interventions: Freeze-dried blueberry powder beverage; Other
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Pain
Interventions: Desmetramadol; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg; Drug
Lead sponsor: Banner Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Resistance Training, Breakfast
Interventions: Breakfast omission, Breakfast consumption; Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lubbock, Texas

Search by objective public record fields.

FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Safety and Tolerability of Lu AG06474 in Healthy Young Men

Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

PACE-PC: Primary Care Management of Adolescent Obesity

Alternative Therapies for Improving Physical Function in Individuals With Stroke

Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding

Lowering Impaired Fasting Glucose Levels With Exercise

Breathe for Hot Flashes Randomized Controlled Trial

A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects

A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function

The HIV, Adipose Tissue Immunology, and Metabolism Study

Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites

A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

The Effect of Breakfast Consumption on Afternoon Resistance Training Performance